Teriparatide in the Treatment of Severe Postmenopausal Osteoporosis: A Cost-Utility Analysis

Teriparatide is a new agent serves as a treatment of choice for severe post-menopausal osteoporotic patients who are at high risk of fracture or have failed or been intolerant of previous osteoporosis therapy. The objective of this study is to estimate the cost-utility of teriparatide compared with...

Descripción completa

Detalles Bibliográficos
Autores principales: Taheri, Saeed, Mirzayeh Fashami, Fatemeh, Peiravian, Farzad, Yousefi, Nazila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Shaheed Beheshti University of Medical Sciences 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6706718/
https://www.ncbi.nlm.nih.gov/pubmed/31531089
http://dx.doi.org/10.22037/ijpr.2019.1100679

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6706718/
https://www.ncbi.nlm.nih.gov/pubmed/31531089
http://dx.doi.org/10.22037/ijpr.2019.1100679

Ejemplares similares